ASCO 2022: 100% Complete Response Rate in MMRd Locally Advanced Rectal Cancer Seen in Pivotal ‘Immunoablative’ Neoadjuvant Immunotherapy Clinical Trial
Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine today by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 14 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer. This new approach of “immunoablative” therapy uses immunotherapy to replace surgery, chemotherapy and radiation to remove cancer.